WO2023049937A3 - Synthetic production of circular dna vectors - Google Patents

Synthetic production of circular dna vectors Download PDF

Info

Publication number
WO2023049937A3
WO2023049937A3 PCT/US2022/077108 US2022077108W WO2023049937A3 WO 2023049937 A3 WO2023049937 A3 WO 2023049937A3 US 2022077108 W US2022077108 W US 2022077108W WO 2023049937 A3 WO2023049937 A3 WO 2023049937A3
Authority
WO
WIPO (PCT)
Prior art keywords
circular dna
dna vectors
methods
synthetic production
pharmaceutical compositions
Prior art date
Application number
PCT/US2022/077108
Other languages
French (fr)
Other versions
WO2023049937A2 (en
Inventor
Jin Huh
Eileen HIGHAM
Jose Lora
Jodi KENNEDY
Anne MAGUIRE
Meisam BAKHSHAYESH
Eliza DORNBUSH
Original Assignee
Intergalactic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intergalactic Therapeutics, Inc. filed Critical Intergalactic Therapeutics, Inc.
Priority to IL311778A priority Critical patent/IL311778A/en
Priority to CA3233230A priority patent/CA3233230A1/en
Priority to AU2022349697A priority patent/AU2022349697A1/en
Publication of WO2023049937A2 publication Critical patent/WO2023049937A2/en
Publication of WO2023049937A3 publication Critical patent/WO2023049937A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Provided herein are improved methods of producing therapeutic circular DNA vectors, pharmaceutical compositions produced by such methods, and methods of using pharmaceutical compositions. The invention is based, at least in part, on cell-free manufacturing processes involving restriction digest and ligation schemes, such as restriction digest processes involving type IIs restriction enzymes. Methods provided herein are amenable to large scale production of high-purity compositions of therapeutic circular DNA vectors.
PCT/US2022/077108 2021-09-27 2022-09-27 Synthetic production of circular dna vectors WO2023049937A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL311778A IL311778A (en) 2021-09-27 2022-09-27 Synthetic production of circular dna vectors
CA3233230A CA3233230A1 (en) 2021-09-27 2022-09-27 Synthetic production of circular dna vectors
AU2022349697A AU2022349697A1 (en) 2021-09-27 2022-09-27 Synthetic production of circular dna vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163248801P 2021-09-27 2021-09-27
US63/248,801 2021-09-27

Publications (2)

Publication Number Publication Date
WO2023049937A2 WO2023049937A2 (en) 2023-03-30
WO2023049937A3 true WO2023049937A3 (en) 2023-08-10

Family

ID=85721330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/077108 WO2023049937A2 (en) 2021-09-27 2022-09-27 Synthetic production of circular dna vectors

Country Status (4)

Country Link
AU (1) AU2022349697A1 (en)
CA (1) CA3233230A1 (en)
IL (1) IL311778A (en)
WO (1) WO2023049937A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123973A1 (en) * 2005-10-19 2009-05-14 Reed Thomas D Methods of Making Modular Fusion Protein Expression Products
US20160257991A1 (en) * 2013-11-29 2016-09-08 Q-Linea Ab Rolling circle amplification method
US20170067097A1 (en) * 2014-04-11 2017-03-09 Redvault Biosciences, Lp Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications
US20190040397A1 (en) * 2015-02-10 2019-02-07 Universite Des Sciences Et Technologies De Lille 1 Method for producing dna vectors from molecular bricks containing sequences of interest
US20200231974A1 (en) * 2017-07-18 2020-07-23 Genovie Ab A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames
WO2020257590A1 (en) * 2019-06-21 2020-12-24 Asklepios Biopharmaceutical, Inc. Production of vectors using phage origin of replication
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123973A1 (en) * 2005-10-19 2009-05-14 Reed Thomas D Methods of Making Modular Fusion Protein Expression Products
US20160257991A1 (en) * 2013-11-29 2016-09-08 Q-Linea Ab Rolling circle amplification method
US20170067097A1 (en) * 2014-04-11 2017-03-09 Redvault Biosciences, Lp Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications
US20190040397A1 (en) * 2015-02-10 2019-02-07 Universite Des Sciences Et Technologies De Lille 1 Method for producing dna vectors from molecular bricks containing sequences of interest
US20200231974A1 (en) * 2017-07-18 2020-07-23 Genovie Ab A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames
WO2020257590A1 (en) * 2019-06-21 2020-12-24 Asklepios Biopharmaceutical, Inc. Production of vectors using phage origin of replication
WO2021055760A1 (en) * 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Also Published As

Publication number Publication date
WO2023049937A2 (en) 2023-03-30
AU2022349697A1 (en) 2024-05-16
IL311778A (en) 2024-05-01
CA3233230A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
WO2007024756A3 (en) Reduced genome e. coli
HUP9901992A2 (en) A mutant e. coli strain with increased succinic acid production
SG151330A1 (en) Process for production of optically active amine derivatives
WO2007047859A3 (en) Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP1095158A4 (en) Process and materials for production of glucosamine
WO2002057474A3 (en) Processes for enhanced production of pantothenate
TW200505939A (en) Process for production of cyclic peptides
WO2002101056A3 (en) Conjugated linoleic acid isomerase and a process for the production of conjugated linoleic acid
MX2022009001A (en) Therapeutic double stranded rna and methods for producing the same.
NZ516893A (en) Metabolic engineering of amino acid production
EP2420561A4 (en) Aspergillus sp. having large-scale genome duplication
WO2023049937A3 (en) Synthetic production of circular dna vectors
JP5344857B2 (en) Method for producing filamentous fungal protease
EP1469738A4 (en) Cheese flavour ingredient and method of its production
ATE383419T1 (en) MUTANE EUBACTERIAL RNA POLYMERASE FOR INCREASE HETEROLOGUE GENE EXPRESSION
WO2022180071A3 (en) Lactic acid bacteria composition for preparing fermented products
HUP0202517A2 (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
CA2484638A1 (en) Polyene polyketides and methods of production
JP2007314434A5 (en)
WO2020047637A8 (en) Genetically modified bacteria producing three dna repair enzymes and method for the evaluation of dna repair activity
WO2023108107A3 (en) Modified immune cells and methods of using the same
CY1105936T1 (en) MUTANT STRAINS ABLE TO PRODUCE PROTEINS CHEMICALLY DIFFERENT BY INCORPORATION OF UNCONVENTIONAL AMINO ACIDS
KR102001602B1 (en) A mineral composition for enhancing enzyme activity of microorganism for preparing meju
WO2020136237A4 (en) Weissella viridescens strain and uses thereof for the synthesis of exopolysaccharides
KR100575058B1 (en) D-Hydantoinase Variants Having Improved Activity for Aromatic Substrates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22873942

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3233230

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2401002018

Country of ref document: TH

Ref document number: 311778

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024006183

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: AU2022349697

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022873942

Country of ref document: EP

Effective date: 20240429

ENP Entry into the national phase

Ref document number: 2022349697

Country of ref document: AU

Date of ref document: 20220927

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22873942

Country of ref document: EP

Kind code of ref document: A2